Nello Mainolfi: Yes. Thanks, Jared. That’s great. And on the STAT3 I&I, maybe I just want to go back to our strategy, which is something that we’ve talked about at the R&D Day. We believe we exist to bring together the power of the technology and unmet needs that are both clinical, commercial, and I would say also the opportunity to do with this technology things that cannot be done with other technology, so I guess another type of unmet need, the technological one. And only I think when we marry those three together, we’re going to go all in. And as you’ve seen with IRAK4 with STAT6 and TYK2, I think we have a very, very easy to articulate value proposition. I hope you guys also feel that way. And these are complete degradation of targets that lead to exceptional anti-inflammatory profiles that are well tolerated, at least in our hands so far.
And so with STAT3, it’s obviously a program that we know, I would argue, better than anybody at this point. We’ve been working on this target for several years. And the reason why you haven’t seen us disclosing more details on STAT3 I&I is because we feel that at this point, we don’t have all the information in hand to being able to say that will fit the profile of the type of programs that we’ve articulated so far. When we do, when it does and would be able to do so, we’ll disclose more.
Unidentified Analyst: Thank you.
Operator: Thank you. The next question comes from Eli Merle from UBS. Please go ahead.
Unidentified Analyst: Hi. This is Jasmine on for Eli. Thanks so much for taking our question. Hi, this is Jasmine on for Eli. Thanks so much for taking our question. What’s your latest thinking on whether you would take both STAT3 and MDM2 into Phase 2? Or is the thinking that you’ll prioritize one over the other, given your focus on immunology? And what would your threshold for success be for each program in thinking about the go and no go decisions?
Nello Mainolfi: Thank you. I think I felt like there were two people, but anyway, I think we got the question. I’m sure there were similar questions. So great question. So maybe I will start with saying that as everything that we’ve done at Kymera for the past almost eight years, all our decisions are going to be data driven. For example, decisions even that we’ve made for programs that we discontinued, for example, 413, even though the molecule was behaving well and was well tolerated was driven by plethora of data, obviously, clinical, commercial landscape to a large extent also MPV analysis that we did. So we’ll apply the same rigor to all programs on our pipeline, whether these are in immunology or in oncology. As we’ve said, in order for us to invest in, let’s say, in these two oncology programs, we need to be able to see in front of us opportunities to impact broad patient populations.
So I think our go criteria for both programs will be driven by opportunities that are both in heme and solid tumors generally at this level. And I think we should probably wait for when we disclose more data later in the year on what exactly the strategy will be. What I will say is that for STAT3, we’ve shown something that has not been shown before, which is this is an active target and we have an active drug. We’ve shown a small data set in December, at ASH will show more later in the year. And in MDM2 we also have an active drug. We’ve showed really few patients data, in November we’ll show much more later in the year. So I think only when we’re able together to look at the totality of the data, you’ll be much clearer what the decision making process is going to look like.
Unidentified Analyst: Great. Thanks so much.
Operator: Thank you. The next question is from the line of Geoff Meacham from Bank of America. Please go ahead.
Unidentified Analyst: Hi. Good morning. This is Susan on for Geoff. Thanks for taking our question. Can you walk us through what the strategy is for indication selection for the immunology programs, the STAT6 and the – sorry, the TYK2 and the IL-4? And just commenting specifically on maybe competitive landscape or maybe what kind of data you’re going to look at prior to initiating first in human studies.
Nello Mainolfi: Okay. So I’m going to take this really high level just because I want to be consistent with our message, which has been that as we get into the clinic in our healthy volunteer studies, at least towards STAT6 and for TYK2, I think at that point we will feel more comfortable talking about later development for several reasons. One, we don’t have to talk about it now, and two, the landscape, as you said, is competitive. And I don’t believe at this point it’s necessary to disclose information that are not needed. But at the high level, what I want to say is – high level for STAT6, I don’t believe that there are well tolerated oral drugs in indications in which dupilumab has been approved that have, as I say, they’re well tolerated, strong activity.
So we have a huge potential in a variety of indications. I don’t have to name them because they’re all well-established from AD, asthma, hopefully soon COPD, chronic rhinosinusitis and others COE. There is actually white space in that area for oral drugs with a good safety profile. So while obviously all of those indications are going to get more and more competitive, given large investments that biopharma is putting into immunology, we’re actually in a really unique position right now going forward. And once we disclose our development plans, you’ll see how actually we would be able – we believe to be really competitive in terms of timing of our trials as well as the design of our trials. With regards to TYK2, it’s obviously a different landscape.
